MedTrace Logo

Combination of Danazole With Berberine in the Treatment of ITP

NCT03909763 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2020-09-25

Study results available
· View outcomes & findings →

Summary

A prospective, multicenter, open-label, Phase II, single arm, trial performed in 6 departments of hematology in China

Conditions

  • Corticosteroid-resistant or Relapsed ITP

Interventions

DRUG

Berberine plus danazol

Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Xiaohui Zhang, MD · Peking University of people's hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-20
Primary Completion
2020-12-30
Completion
2021-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03909763 on ClinicalTrials.gov